China Resources Shuanghe announced that Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Drug GMP Compliance Inspection Notice” issued by the Beijing Drug Administration. The scope of inspection was the production line of the softgel capsule in the comprehensive manufacturing workshop of China Resources Shuanghe Pharmaceutical Co., Ltd. to produce softgels, alfacalcidol softgels. The inspection period was from November 26, 2025 to November 28, 2025, and the conclusion was that it complied with the requirements of the “Pharmaceutical Production Quality Management Code” and appendices. The inspection project was an inspection under the condition of the original plant and equipment, and no capital was invested.

Zhitongcaijing · 4d ago
China Resources Shuanghe announced that Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Drug GMP Compliance Inspection Notice” issued by the Beijing Drug Administration. The scope of inspection was the production line of the softgel capsule in the comprehensive manufacturing workshop of China Resources Shuanghe Pharmaceutical Co., Ltd. to produce softgels, alfacalcidol softgels. The inspection period was from November 26, 2025 to November 28, 2025, and the conclusion was that it complied with the requirements of the “Pharmaceutical Production Quality Management Code” and appendices. The inspection project was an inspection under the condition of the original plant and equipment, and no capital was invested.